(0.87%) 5 126.25 points
(0.20%) 38 364 points
(1.15%) 17 770 points
(0.54%) $84.02
(-2.08%) $1.604
(0.39%) $2 351.60
(1.07%) $27.65
(1.41%) $933.50
(0.02%) $0.932
(0.03%) $10.95
(0.02%) $0.799
(0.02%) $92.19
Live Chart Being Loaded With Signals
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy...
Stats | |
---|---|
Today's Volume | 454 575 |
Average Volume | 823 214 |
Market Cap | 1.34B |
EPS | $0 ( 2024-02-21 ) |
Next earnings date | ( $-0.970 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.55 |
ATR14 | $0.0200 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Jarrett Jennifer | Sell | 11 551 | Common Stock |
2024-03-18 | Jarrett Jennifer | Sell | 12 153 | Common Stock |
2024-03-18 | Jarrett Jennifer | Sell | 1 296 | Common Stock |
2024-02-26 | Jarrett Jennifer | Sell | 24 555 | Common Stock |
2024-02-27 | Jarrett Jennifer | Sell | 34 070 | Common Stock |
INSIDER POWER |
---|
95.52 |
Last 100 transactions |
Buy: 19 279 293 | Sell: 529 920 |
Volume Correlation
Arcus Biosciences Inc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Arcus Biosciences Inc Correlation - Currency/Commodity
Arcus Biosciences Inc Financials
Annual | 2023 |
Revenue: | $117.00M |
Gross Profit: | $101.00M (86.32 %) |
EPS: | $-4.15 |
Q4 | 2023 |
Revenue: | $31.00M |
Gross Profit: | $26.00M (83.87 %) |
EPS: | $-1.080 |
Q3 | 2023 |
Revenue: | $32.00M |
Gross Profit: | $29.00M (90.63 %) |
EPS: | $-0.950 |
Q2 | 2023 |
Revenue: | $29.00M |
Gross Profit: | $25.00M (86.21 %) |
EPS: | $-1.020 |
Financial Reports:
No articles found.
Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators